3-[(5-Indazolylamino)-methylene]-1,3-dihydro-indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-[(5-Indazolylamino)-methylene]-1,3-dihydro-indol-2-one
• 英文别名: (3Z)-3-[(1H-indazol-5-ylamino)methylidene]-1H-indol-2-one
• 化学式: C₁₆H₁₂N₄O
• 分子量: 276.297
• InChiKey: UKTMBEYKEGEXPG-LCYFTJDESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.8
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
  申请人：——

  公开号：US20030199478A1

  公开（公告）日：2003-10-23

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调控、调节和/或抑制异常细胞增殖。
• [EN] SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS<br/>[FR] DERIVES SUBSTITUES D'OXINDOLE EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE ET DE LA SERINE/THREONINE KINASE
  申请人：GLAXO GROUP LIMITED

  公开号：WO1999015500A1

  公开（公告）日：1999-04-01

  (EN) Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7-sulfonyl -C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.(FR) L'invention concerne des composés représentés par la formule (I).X y est N, CH, CCF3, ou C(C1-12 aliphatique); R4 est acide sulfonique, C1-12 aliphatique sulfonyle, sulphonyle C1-12 aliphatique, C1-12 aliphatique sulfonyle-C1-16, aliphatique, C1-16 aliphatique-amino, R7-sulfonyle, R7-sulfonyle -C1-12 aliphatique, R7-aminosulfonyle, R7-aminosulfonyle-C1-12, aliphatique, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatique, aminosulfonylamino, di-C1-12 aliphatique amino, di-C1-12 aliphatique aminocarbonyle, di-C1-12 aliphatique aminosulfonyle, di-C1-12 aliphatique amino, di-C1-12 aliphatique aminocarbonyle, di-C1-12 aliphatique aminosulfonyle C1-12 aliphatique, (R8)1-13-arylamino, (R8)1-13-arylsulfonyle, (R8)1-13-arylaminosulfonyle, (R8)1-13-arylsulfonylamino, het-amino, het-sulfonyle, het-aminosulfonyle, aminoiminoamino ou aminoiminoaminosulfonyle; R5 est hydrogène; en outre, R4 et R5 sont éventuellement réunis afin de former un cycle. L'invention concerne également des formulations pharmaceutiques qui renferment ces dérivés et leur utilisation thérapeutique, en particulier dans le traitement de maladies à médiation CDK2, telles que l'alopécie provoquée par la chimiothérapie ou la radiothérapie anticancéreuses.

  化合物的式子为(I)：其中X为N、CH、CCF3或C(C1-12脂肪基)；R4为磺酸、C1-12脂肪基磺酰、磺酰-C1-12脂肪基、C1-12脂肪基磺酰-C1-6脂肪基、C1-6脂肪基氨基、R7磺酰、R7磺酰-C1-12脂肪基、R7氨基磺酰、R7氨基磺酰-C1-12脂肪基、R7磺酰氨基、R7磺酰氨基-C1-12脂肪基、氨基磺酰氨基、双C1-12脂肪基氨基、双C1-12脂肪基氨基羰基、双C1-12脂肪基氨基磺酰、双C1-12脂肪基氨基、双C1-12脂肪基氨基羰基、双C1-12脂肪基氨基磺酰-C1-12脂肪基、(R8)1-3-芳基氨基、(R8)1-3-芳基磺酰、(R8)1-3-芳基氨基磺酰、(R8)1-3-芳基磺酰氨基、杂环氨基、杂环磺酰、杂环氨基磺酰、氨基亚氨基或氨基亚氨基磺酰；R5为氢；并且R4和R5可以选择性地连接形成融合环。其中药物制剂包括它们及其在治疗中的使用，特别是在CDK2活性介导的疾病治疗中，例如由癌症化疗或放疗引起的脱发。
• Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
  申请人：——

  公开号：US20030004351A1

  公开（公告）日：2003-01-02

  Compounds of formula (I): wherein X is N, CH, CCF 3 , or C(C 1-12 aliphatic); R 4 is sulfonic acid, C 1-12 aliphatic-sulfonyl, sulfonyl-C 1-12 aliphatic, C 1-12 aliphatic-sulfonyl-C 1-6 aliphatic, C 1-6 aliphatic-amino, R 7 -sulfonyl, R 7 sulfonyl-C 1-12 aliphatic, R 7 -aminosulfonyl, R 7 -aminosulfonyl-C 1-12 aliphatic, R 7 -sulfonylamino, R 7 -sulfonylamino-C 1-12 aliphatic, aminosulfonylamino, di-C 1-12 aliphatic amino, di-C 1-12 aliphatic aminocarbonyl, di-Cl 1-12 aliphatic aminosulfonyl, di-C 1-12 aliphatic amino, di-C 1-12 aliphatic aminocarbonyl, di-C 1-12 aliphatic aminosulfonyl-C 1-12 aliphatic, (R 8 ) 1-3 -Arylamino, (R 8 ) 1-3 -Arylsulfonyl, (R 8 ) 1-3 -Aryl-aminosulfonyl, (R 8 ) 1-3 -Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R 5 is hydmogen; and further wherein R 4 and R 5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

  式(I)的化合物：其中X为N、CH、CCF3或C（C1-12脂肪族）；R4为磺酸、C1-12脂肪族磺酰基、磺酰-C1-12脂肪族、C1-12脂肪族-磺酰基-C1-6脂肪族、C1-6脂肪族-氨基、R7-磺酰基、R7-磺酰基-C1-12脂肪族、R7-氨基磺酰基、R7-氨基磺酰基-C1-12脂肪族、R7-磺酰胺基、R7-磺酰胺基-C1-12脂肪族、氨基磺酰胺基、二C1-12脂肪族氨基、二C1-12脂肪族氨基甲酰基、二C1-12脂肪族氨基磺酰基、二C1-12脂肪族氨基、二C1-12脂肪族氨基甲酰基、二C1-12脂肪族氨基磺酰基-C1-12脂肪族、（R8）1-3-芳基氨基、（R8）1-3-芳基磺酰基、（R8）1-3-芳基氨基磺酰基、（R8）1-3-芳基磺酰胺基、Het-氨基、Het-磺酰基、Het-氨基磺酰基、氨基亚胺基或氨基亚胺基磺酰基；R5为氢；进一步地，其中R4和R5可选地结合形成融合环，以及包含它们的制药配方和它们在治疗中的用途，特别是在治疗CDK2活性介导的疾病方面，如由癌症化疗或放疗引起的脱发。
• Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects
  申请人：——

  公开号：US20030069430A1

  公开（公告）日：2003-04-10

  Compounds of formula (I): wherein X is N, CH, CCF 3 , or C(C 1-12 aliphatic); R 4 is sulfonic acid, C 1-12 aliphatic-sulfonyl, sulfonyl-C 1-12 aliphatic, C 1-12 aliphatic-sulfonyl-C 1-6 aliphatic, C 1-6 aliphatic-amino, R 7 -sulfonyl, R 7 sulfonyl-C 1-12 aliphatic, R 7 -aminosulfonyl, R 7 aminosulfonyl-C 1-12 aliphatic, R 7 -sulfonylamino, R 7 -sulfonylamino-C 1-12 aliphatic, aminosulfonylamino, di-C 1-12 aliphatic amino, di-C 1-12 aliphatic aminocarbonyl, di-C 1-12 aliphatic aminosulfonyl, di-C 1-12 aliphatic amino, di-C 1-12 aliphatic aminocarbonyl, di-C 1-12 aliphatic aminosulfonyl-C 1-12 aliphatic, (R 8 ) 1-3 -Arylamino, (R 8 ) 1-3 -Arylsulfonyl, (R 8 ) 1-3 -Aryl-aminosulfonyl, (R 8 ) 1-3 -Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R 5 is hydrogen; and further wherein R 4 and R 5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

  化合物的公式（I）：其中X为N，CH，CCF3或C（C1-12脂肪族）; R4为磺酸，C1-12脂肪族磺酰基，磺酰基-C1-12脂肪族，C1-12脂肪族磺酰基-C1-6脂肪族，C1-6脂肪族氨基，R7-磺酰基，R7磺酰基-C1-12脂肪族，R7-氨基磺酰基，R7氨基磺酰基-C1-12脂肪族，R7-磺酰胺基，R7-磺酰胺基-C1-12脂肪族，氨基磺酰胺基，二C1-12脂肪族氨基，二C1-12脂肪族氨基甲酰基，二C1-12脂肪族氨基磺酰基，二C1-12脂肪族氨基，二C1-12脂肪族氨基甲酰基，二C1-12脂肪族氨基磺酰基-C1-12脂肪族，（R8）1-3-芳基氨基，（R8）1-3-芳基磺酰基，（R8）1-3-芳基氨基磺酰基，（R8）1-3-芳基磺酰胺基，Het-氨基，Het-磺酰基，Het-氨基磺酰基，氨基亚氨基，或氨基亚氨基磺酰基，R5为氢; 进一步地，其中R4和R5可选择地连接以形成融合环，包括它们的制药配方以及它们在治疗中的应用，特别是在CDK2活性介导的疾病治疗中，例如由癌症化疗或放疗引起的脱发。
• 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
  申请人：——

  公开号：US20030225152A1

  公开（公告）日：2003-12-04

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调制和/或抑制异常细胞增殖。